--- title: "Neoadjuvant Renal Cell Cancer NRG GU012 (SAMURAI) | Sutter Health" description: "Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)" url: "https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-renal-cell-cancer-nrg-gu012-samurai-1094720569" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Neoadjuvant Renal Cell Cancer NRG GU012 (SAMURAI) # Neoadjuvant Renal Cell Cancer NRG GU012 (SAMURAI) **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-renal-cell-cancer-nrg-gu012-samurai-1094720569#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05327686?term=gu012&rank=1). #### Locations - Sutter Health System Wide #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI) This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). ![Christopher U Jones, M.D., FACR](https://dyn.mktgcdn.com/p/6fMCH4vO97TB6M5QvU1pl5Qui1fViPD5KLLubfev_dQ/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Christopher U Jones, M.D., FACR Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/christopher-u-jones-md-facr-1049681071) ## Sub-Investigators [Hubert Y Pan, M.D., M.S.](https://www.sutterhealth.org/research/investigators/hubert-y-pan-md-ms-1049681154) , [Nitin Rohatgi, M.D., MBA](https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017) ## Email us to enroll - [Email Sutter Health System Wide](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Neoadjuvant%20Renal%20Cell%20Cancer%20NRG%20GU012%20\(SAMURAI\)%20in%20Sutter%20Health%20System%20Wide&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Adjuvant Kidney Cancer STRIKE A032201](https://www.sutterhealth.org/research/clinical-trials/adjuvant-kidney-cancer-strike-a032201-2015845327) Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE **Status:** Open to Enrollment - Clinical trial ### [Advanced Clear Cell Renal Cell Carcinoma S2419](https://www.sutterhealth.org/research/clinical-trials/advanced-clear-cell-renal-cell-carcinoma-s2419-2073485716) Phase III Double Blinded Trial of Immune-Based Therapy With a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma \[BioFront Trial\] **Status:** Open to Enrollment - Clinical trial ### [Advanced Cervical Cancer NRG GY037](https://www.sutterhealth.org/research/clinical-trials/advanced-cervical-cancer-nrg-gy037-2097344123) A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer **Status:** Open to Enrollment - Clinical trial ### [Advanced Staged Cancer Targeted Therapy ASCO TAPUR](https://www.sutterhealth.org/research/clinical-trials/targeted-agent-and-profiling-utilization-registry-tapur-st-1049141787) Targeted Agent and Profiling Utilization Registry (TAPUR) Study **Status:** Open to Enrollment - Clinical trial ### [Adverse Effects of Chemotherapy Shengbai Solution](https://www.sutterhealth.org/research/clinical-trials/adverse-effects-of-chemotherapy-shengbai-solution-1097505286) A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-renal-cell-cancer-nrg-gu012-samurai-1094720569#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Neoadjuvant Renal Cell Cancer NRG GU012 (SAMURAI)"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-renal-cell-cancer-nrg-gu012-samurai-1094720569#medicalwebpage","name":"Neoadjuvant Renal Cell Cancer NRG GU012 (SAMURAI)","description":"Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)","url":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-renal-cell-cancer-nrg-gu012-samurai-1094720569","inLanguage":"en-US","dateModified":"2026-05-21","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-renal-cell-cancer-nrg-gu012-samurai-1094720569#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-renal-cell-cancer-nrg-gu012-samurai-1094720569#breadcrumblist"},"mentions":[{"@type":"Person","name":"Christopher U Jones, M.D., FACR","url":"https://www.sutterhealth.org/research/investigators/christopher-u-jones-md-facr-1049681071","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-renal-cell-cancer-nrg-gu012-samurai-1094720569#medicaltrial","name":"Neoadjuvant Renal Cell Cancer NRG GU012 (SAMURAI)","alternateName":"Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)","url":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-renal-cell-cancer-nrg-gu012-samurai-1094720569","description":"Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI) This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic).","identifier":"NCT05327686","code":{"@type":"MedicalCode","codeValue":"NCT05327686","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT05327686?term=gu012&rank=1","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Renal Cancer"},{"@type":"MedicalCondition","name":"Kidney Disease"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sutter Health System Wide"}]} ```